VSA012 not checked
Bisirna Therapeutics (Suzhou) Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “A study of the efficacy and safety of VSA012 Injection compared to eculizumab for 24 weeks in patients with PNH.”In the company’s words, NCT07816237 on ClinicalTrials.gov
Other drugs for Paroxysmal Nocturnal Hemoglobinuria, PNH
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- MY008211AWuhan Createrna Science and Technology Co., Ltd · Phase 3
- CrovalimabRoche · Phase 3
- DanicopanAlexion Pharmaceuticals, Inc. · Phase 3
- IptacopanNovartis · Phase 3
- FXS6837Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Phase 3
Coming up2
- 28 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 30 Sep 2027 | A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy | |
| Phase 1Active, not recruiting | Aug 2026 | A Phase I Clinical Study of VSA012 in Healthy Volunteers | |
| Phase 1Active, not recruiting | 28 Feb 2027 | Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal Hemoglobinuria |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026